Global prevalence and major risk factors of diabetic retinopathy - PubMed (original) (raw)

doi: 10.2337/dc11-1909. Epub 2012 Feb 1.

Sophie L Rogers, Ryo Kawasaki, Ecosse L Lamoureux, Jonathan W Kowalski, Toke Bek, Shih-Jen Chen, Jacqueline M Dekker, Astrid Fletcher, Jakob Grauslund, Steven Haffner, Richard F Hamman, M Kamran Ikram, Takamasa Kayama, Barbara E K Klein, Ronald Klein, Sannapaneni Krishnaiah, Korapat Mayurasakorn, Joseph P O'Hare, Trevor J Orchard, Massimo Porta, Mohan Rema, Monique S Roy, Tarun Sharma, Jonathan Shaw, Hugh Taylor, James M Tielsch, Rohit Varma, Jie Jin Wang, Ningli Wang, Sheila West, Liang Xu, Miho Yasuda, Xinzhi Zhang, Paul Mitchell, Tien Y Wong; Meta-Analysis for Eye Disease (META-EYE) Study Group

Collaborators, Affiliations

Global prevalence and major risk factors of diabetic retinopathy

Joanne W Y Yau et al. Diabetes Care. 2012 Mar.

Abstract

Objective: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes.

Research design and methods: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20-79 years.

Results: A total of 35 studies (1980-2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5-34.8) for any DR, 6.96% (6.87-7.04) for proliferative DR, 6.81% (6.74-6.89) for diabetic macular edema, and 10.2% (10.1-10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A(1c), and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes.

Conclusions: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.

PubMed Disclaimer

References

    1. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179–183 - PubMed
    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14 - PubMed
    1. Yang W, Lu J, Weng J, et al. ; China National Diabetes and Metabolic Disorders Study Group Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090–1101 - PubMed
    1. Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci 2005;46:2328–2333 - PubMed
    1. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006;141:446–455 - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources